These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32183176)

  • 1. Hepatitis C Virus: Evading the Intracellular Innate Immunity.
    Ferreira AR; Ramos B; Nunes A; Ribeiro D
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
    Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
    J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection.
    Wong MT; Chen SS
    Cell Mol Immunol; 2016 Jan; 13(1):11-35. PubMed ID: 25544499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into antiviral innate immunity revealed by studying hepatitis C virus.
    Horner SM
    Cytokine; 2015 Aug; 74(2):190-7. PubMed ID: 25819428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current progress in host innate and adaptive immunity against hepatitis C virus infection.
    Shi J; Li Y; Chang W; Zhang X; Wang FS
    Hepatol Int; 2017 Jul; 11(4):374-383. PubMed ID: 28643186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response.
    Bode JG; Brenndörfer ED; Häussinger D
    Biol Chem; 2008 Oct; 389(10):1283-98. PubMed ID: 18713016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mononuclear phagocyte system in hepatitis C virus infection.
    Yang Y; Tu ZK; Liu XK; Zhang P
    World J Gastroenterol; 2018 Nov; 24(44):4962-4973. PubMed ID: 30510371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming.
    Ellwanger JH; Kaminski VL; Valverde-Villegas JM; Simon D; Lunge VR; Chies JAB
    Infect Genet Evol; 2018 Dec; 66():376-391. PubMed ID: 28811194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?
    Yang DR; Zhu HZ
    World J Gastroenterol; 2015 Apr; 21(13):3786-800. PubMed ID: 25852264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate and adaptive immune responses in HCV infections.
    Heim MH; Thimme R
    J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus-mediated modulation of cellular immunity.
    Brenndörfer ED; Sällberg M
    Arch Immunol Ther Exp (Warsz); 2012 Oct; 60(5):315-29. PubMed ID: 22911132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence.
    Quarleri JF; Oubiña JR
    Ann Hepatol; 2016; 15(1):17-26. PubMed ID: 26626636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate detection of hepatitis B and C virus and viral inhibition of the response.
    Yi Z; Chen J; Kozlowski M; Yuan Z
    Cell Microbiol; 2015 Sep; 17(9):1295-303. PubMed ID: 26243406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immunity against hepatitis C virus.
    Xu Y; Zhong J
    Curr Opin Immunol; 2016 Oct; 42():98-104. PubMed ID: 27366996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.
    Zhao Y; Cao X; Guo M; Wang X; Yu T; Ye L; Han L; Hei L; Tao W; Tong Y; Xu Y; Zhong J
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30111563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver.
    Mitchell AM; Stone AE; Cheng L; Ballinger K; Edwards MG; Stoddard M; Li H; Golden-Mason L; Shaw GM; Khetani S; Rosen HR
    mBio; 2015 Feb; 6(2):e02510. PubMed ID: 25714713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus--T-cell responses and viral escape mutations.
    Petrovic D; Dempsey E; Doherty DG; Kelleher D; Long A
    Eur J Immunol; 2012 Jan; 42(1):17-26. PubMed ID: 22125159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interplay between Antiviral Signalling and Carcinogenesis in Human Papillomavirus Infections.
    Ferreira AR; Ramalho AC; Marques M; Ribeiro D
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.